- Home
- RYDE vs CVRX Comparison
RYDE vs CVRX Comparison
Compare RYDE & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- CVRX
- Stock Information
- Founded
- RYDE 2014
- CVRX 2000
- Country
- RYDE Singapore
- CVRX United States
- Employees
- RYDE N/A
- CVRX N/A
- Industry
- RYDE
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RYDE
- CVRX Health Care
- Exchange
- RYDE NYSE
- CVRX Nasdaq
- Market Cap
- RYDE 5.2M
- CVRX 174.4M
- IPO Year
- RYDE 2024
- CVRX 2021
- Fundamental
- Price
- RYDE $0.37
- CVRX $7.44
- Analyst Decision
- RYDE
- CVRX Buy
- Analyst Count
- RYDE 0
- CVRX 7
- Target Price
- RYDE N/A
- CVRX $14.50
- AVG Volume (30 Days)
- RYDE 29.7M
- CVRX 161.7K
- Earning Date
- RYDE 05-02-2025
- CVRX 07-28-2025
- Dividend Yield
- RYDE N/A
- CVRX N/A
- EPS Growth
- RYDE N/A
- CVRX N/A
- EPS
- RYDE N/A
- CVRX N/A
- Revenue
- RYDE $6,557,978.00
- CVRX $52,870,000.00
- Revenue This Year
- RYDE $21.13
- CVRX $11.53
- Revenue Next Year
- RYDE $13.43
- CVRX $18.61
- P/E Ratio
- RYDE N/A
- CVRX N/A
- Revenue Growth
- RYDE 3.27
- CVRX 25.62
- 52 Week Low
- RYDE $0.16
- CVRX $4.30
- 52 Week High
- RYDE $22.49
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- CVRX 61.51
- Support Level
- RYDE N/A
- CVRX $6.30
- Resistance Level
- RYDE N/A
- CVRX $7.21
- Average True Range (ATR)
- RYDE 0.00
- CVRX 0.35
- MACD
- RYDE 0.00
- CVRX 0.16
- Stochastic Oscillator
- RYDE 0.00
- CVRX 83.24
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.